ClinConnect ClinConnect Logo
Search / Trial NCT02098200

Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™

Launched by 4TECH CARDIO LTD. · Mar 25, 2014

Trial Information

Current as of August 02, 2025

Completed

Keywords

Tricuspid Regurgitation Repair Outcomes

ClinConnect Summary

Implantation Procedure: Unlike the standard open chest, arrested heart approach, the 4TECH TriCinch System™ provides a percutaneous solution for tricuspid valve regurgitation treatment: this procedure is performed through deep sedation, while the heart is beating, without the need for respiratory assistance.

The TriCinch System™ consists of a Delivery System that enables transcatheter placement of an implant that can be adjusted to correct Tricuspid valve regurgitation. The TriCinch Delivery System is inserted from the femoral vein to access the right atrium of the heart. At the end of the...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Functional symptomatic tricuspid regurgitation (TR) 2+ to 4+ on a scale of 4+ (moderate to severe), with annular dilatation greater than 40mm.
  • Signed informed consent form prior to any study-related procedure.
  • Available and able to return to the study site for post-procedural follow-up examination
  • Eighteen (18) years of age or older.
  • Exclusion Criteria:
  • Requirement for concomitant cardiac procedure (other than atrial fibrillation correction surgery, closure of PFO (Patent Foramen Ovale) or ASD (Atrial Septal Defect), or PTCA (percutaneous treatment of coronary artery) or CAD (coronary artery bypass surgery) from 1 to 3 months after or before other procedure.
  • Presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year.
  • Cerebro-vascular event within the past 6 months.
  • History of mitral/tricuspid endocarditis within the last 12 months.
  • Organic tricuspid disease.
  • Contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately premeditated.
  • Severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg, measurement done by sphygmomanometer with stethoscope, allow the patient to sit for at least 5 minutes before beginning BP measurements).
  • Female patient is pregnant (urine HCG test result positive) or lactating.
  • Known alcohol or drug abuser.
  • Currently participating in the study of an investigational drug or device.
  • At heart team's judgement, patient IVC dimension is not adequate for device implantation.

About 4tech Cardio Ltd.

4tech Cardio Ltd. is a pioneering medical device company dedicated to advancing cardiovascular health through innovative technologies. Specializing in the development of minimally invasive solutions, the company focuses on enhancing patient outcomes by addressing unmet clinical needs in the treatment of cardiovascular diseases. With a commitment to rigorous research and clinical trials, 4tech Cardio Ltd. aims to deliver safe and effective products that improve the quality of life for patients worldwide. Through collaboration with healthcare professionals and regulatory bodies, the company strives to maintain the highest standards of safety and efficacy in its offerings.

Locations

Padova, , Italy

Toulouse, , France

Lyon, , France

Paris, , France

Paris, , France

Bonn, , Germany

Frankfurt Am Main, , Germany

Hamburg, , Germany

Milan, Lombardy, Italy

Pisa, Tuscany, Italy

Catania, , Italy

Massa, , Italy

Milano, , Italy

Roma, , Italy

Nieuwegein, , Netherlands

Patients applied

0 patients applied

Trial Officials

Antonio Colombo, MD

Principal Investigator

San Raffaele Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials